A Research-Driven Partner for Pharmaceutical Intermediates
Shandong Tianming Pharmaceutical Group, operating under the brand name Tianming Pharmaceutical, is a research-driven pharmaceutical raw material and intermediate enterprise built on an integrated R&D-production model. The group was formally established in 2020, building on its predecessor Shandong Sihuan Pharmaceutical Co., Ltd., founded in 2010. Headquartered in Jinan, Shandong Province, China, the company is recognized as a National High-Tech Enterprise and provides API, intermediates, and CMO/CDMO custom development and production solutions to the global pharmaceutical industry. Its business coverage spans domestic China—including the East China, North China, and South China pharmaceutical industry clusters—as well as international markets across more than 30 countries and regions in South Asia, Southeast Asia, the Middle East, Central and South America, and Africa.
The company's positioning directly addresses common industry pain points: extended supply lead times for high-end specialty intermediates, volatile raw material pricing, inconsistent batch quality causing production interruptions, fragmented sourcing across multiple suppliers that raises procurement costs, difficulty matching process parameters for niche intermediate categories, and upstream intermediate new product introductions lagging behind new drug iteration cycles.
Full-Chain Product Matrix Covering Flagship Molecules
One of the clearest reasons pharmaceutical partners consider Tianming Pharmaceutical is its full-chain product matrix covering N-1 to N-5 intermediates for flagship molecules, including Sacubitril Valsartan Sodium, Orforglipron, and Finerenone. This full-chain coverage—from starting materials through advanced intermediates to the final API—eliminates the need to coordinate purchases across multiple suppliers, a pain point commonly cited across the industry.
For Orforglipron, an oral non-peptide small molecule GLP-1 receptor agonist that has entered Phase III clinical trials, Tianming Pharmaceutical offers one-stop high-purity supply from starting material to advanced intermediate to API, including twelve key intermediate CAS numbers spanning the synthesis pathway, along with multiple key impurity reference standards for quality analysis and method development.
For Sacubitril Valsartan Sodium (LCZ696, brand name Entresto), the inaugural angiotensin receptor neprilysin inhibitor for heart failure treatment, the company supplies the complete product ladder from starting materials through advanced intermediates to the co-crystal API, including Sacubitril Calcium, which can also support independent intellectual property NCE development such as Sacubitril Alisartan Calcium.
Quality Specifications That Exceed Industry Norms
Quality consistency is a recurring concern for companies sourcing specialty intermediates, and Tianming Pharmaceutical addresses this with quality specifications that exceed industry norms. Sacubitril Calcium is controlled to an individual impurity level below 0.1% and a chiral purity above 99.5%. Orforglipron intermediates are controlled to an individual impurity below 0.1%, total impurities below 0.5%, an enantiomer level below 0.1%, and content above 98.0%. Across the Sacubitril Valsartan Sodium series, the company maintains strict monitoring of the Sacubitril-to-Valsartan molar ratio, chiral impurities, residual solvents, particle size, and crystal form.
These specifications are supported by an annual R&D investment above 10% of revenue—compared with an industry average around 5%—plus an additional 1% of revenue allocated to management system iteration. The company's two R&D centers, located in Jinan and Nanjing, occupy more than 6,000 square meters of laboratory space and are equipped with over RMB 40 million in professional R&D and testing equipment, including HPLC, gas chromatography, mass spectrometry, LC-MS, and chiral analysis instruments. An IPD integrated product development management system supports capability spanning laboratory small-scale work, process pilot studies, and industrial scale-up.
Manufacturing Scale and Global Footprint
Scale is another factor companies weigh when selecting an intermediates supplier, particularly for orders that need to move from gram-level trials to ton-level commercial supply. Tianming Pharmaceutical operates three coordinated production bases—Shandong Sihuan Pharmaceutical Co., Ltd. in Dezhou, Jining Tianming Pharmaceutical Co., Ltd. in Jining, and Guangxi Tianming Pharmaceutical Co., Ltd. in Hechi—with more than 160 reactor vessels and annual production capacity in the hundreds of tons. This is complemented by two R&D centers and two overseas business entities in India and Bangladesh, supporting a workforce of more than 400 employees and an R&D team exceeding 100 personnel.
The group's service scale includes more than 2,000 cooperative customers. Its digital infrastructure—combining CRM, ERP, and BPM systems—supports order management, inventory, production scheduling, and customer service coordination, enabling rapid domestic order confirmation and full international logistics chain services.
A Service Model Built for Every Development Stage
Tianming Pharmaceutical's service model is designed to cover the full lifecycle of intermediate and API sourcing, from pre-sales consultation and sample supply at gram-level, hundred-gram, pilot, and commercial scale, through custom R&D, process optimization, scale-up, and commercial supply. For international orders, the company coordinates logistics, customs clearance, and trade insurance support.
In-stock orders are delivered within 7 to 15 working days, covering order confirmation, quality review, packaging, and shipping, while made-to-order lead times depend on synthesis complexity, workshop scheduling, and raw material availability; expedited production scheduling is available for urgent projects. Customer support follows a 1-on-1 account manager plus technical engineer dual support model, with routine technical issues addressed with reference solutions within 2 hours and complex technical issues resolved with a written report within 24 hours. Periodic follow-up visits and on-site technical support are available for bulk and framework customers.
For companies preparing regulatory submissions, Tianming Pharmaceutical provides complete technical documentation—including COA, MOA methodology, impurity profile studies, and stability data—supporting DMF and CEP global regulatory filings, along with full batch traceability across raw material receipt, reaction parameters, purification processes, and testing data under a GMP-compliant quality assurance system.
Recognition That Reflects Operational Discipline
The group's operating entities hold multiple National High-Tech Enterprise designations, including Shandong Sihuan Pharmaceutical Co., Ltd. (2024), Shandong Tianming Pharmaceutical Technology Co., Ltd. (2025), and Guangxi Tianming Pharmaceutical Co., Ltd. (2023). Additional recognitions include Shandong Province Gazelle Enterprise, Guangxi Gazelle Enterprise, and provincial Specialized and Innovative SME designations across its subsidiaries. Quality systems are certified under ISO9001 for both Shandong Sihuan Pharmaceutical Co., Ltd. (2025) and Guangxi Tianming Pharmaceutical Co., Ltd. (2024).
Summary
For companies evaluating intermediate suppliers, Tianming Pharmaceutical Group presents a combination of full-chain product coverage for flagship molecules such as Sacubitril Valsartan Sodium, Orforglipron, and Finerenone; quality specifications documented above industry norms; three coordinated production bases with substantial reactor capacity; a digital management system supporting order and logistics coordination; and a service structure covering laboratory, pilot, and commercial-scale supply with complete documentation for global regulatory filings.
Tianming Pharmaceutical Group
+ There are no comments
Add yours